Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Schizophrenia

Free Subscription 26.10.2026 1 Am J Med Genet B Neuropsychiatr Genet 3 Biol Psychiatry 1 J Clin Psychopharmacol 1 Pharmacopsychiatry 4 Psychiatr Clin North Am 3 Psychiatry Res 9 Schizophr Res

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Med Genet B Neuropsychiatr Genet

1. SERRETTI A
   Polygenic Liability for Major Psychiatric Disorders and Clinical Features of Schizophrenia.
   Am J Med Genet B Neuropsychiatr Genet. 2026 Oct 19. doi: 10.1002/ajmg.b.70039.
   PubMed         Abstract available
   
   

   
   Biol Psychiatry

2. VIEIRA S, Aleman Y, Bici L, Meijer J, et al
   Positive-affective and negative-cognitive brain-behavior axes in clinical high risk for psychosis.
   Biol Psychiatry. 2026 Oct 23:S0006-3223(26)01614.
   PubMed         Abstract available
   
   
3. HUANG H, Palaniyappan L, Li H, Zhou J, et al
   Thalamocortical dysconnectivity shapes cortical hierarchy disruption across illness durations in schizophrenia.
   Biol Psychiatry. 2026 Oct 21:S0006-3223(26)01613.
   PubMed         Abstract available
   
   
4. SLIFSTEIN M, Gil R, Weinstein J, Van Snellenberg J, et al
   Simultaneous measurement of Midbrain and Striatal Dopamine in Schizophrenia using an agonist radiotracer.
   Biol Psychiatry. 2026 Oct 21:S0006-3223(26)01612.
   PubMed         Abstract available
   
   

   
   J Clin Psychopharmacol

5. MILLER BJ, Peeples D
   Psychosis as an Adverse Effect of Antibiotics in Children and Adolescents.
   J Clin Psychopharmacol. 2026 Oct 19. doi: 10.1097/JCP.0000000000002252.
   PubMed         Abstract available
   
   

   
   Pharmacopsychiatry

6. SERRETTI A
   Single-Item Anhedonia in Schizophrenia Marks Illness Severity but Does Not Independently Predict Outcomes: An Item-Level Reanalysis of the Clinical Antipsychotic Trials of Intervention Effectiveness Trial.
   Pharmacopsychiatry. 2026 Oct 19. doi: 10.1055/a-2975-2221.
   PubMed         Abstract available
   
   

   
   Psychiatr Clin North Am

7. DELCOURT F, Nilsson LS, Rasmussen AR
   Imagination and Its Disorders in Mental State Examination.
   Psychiatr Clin North Am. 2026;49:693-705.
   PubMed         Abstract available
   
   
8. NORDGAARD J, Henriksen MG
   Delusions: Concept, Structure, and Clinical Boundaries.
   Psychiatr Clin North Am. 2026;49:655-667.
   PubMed         Abstract available
   
   
9. MCKENNA P, Yildirim B
   Formal Thought Disorders.
   Psychiatr Clin North Am. 2026;49:641-653.
   PubMed         Abstract available
   
   
10. PARNAS J, Sandsten KE
    Disorder of Basic Selfhood in the Schizophrenia Spectrum: A Novel Phenotype.
    Psychiatr Clin North Am. 2026;49:613-622.
    PubMed         Abstract available
    
    

    
    Psychiatry Res

11. JAYASANKAR P, Balachander S, Nayok SB, Singh A, et al
    A unified general cognitive factor explains impairment across schizophrenia, bipolar disorder, OCD and substance use disorder.
    Psychiatry Res. 2026;367:117519.
    PubMed         Abstract available
    
    
12. WEI Y, Siafis S, Schneider-Thoma J, Kim DD, et al
    Treatment- and sham-related improvement and associated factors in non-invasive brain stimulation studies in treatment-resistant schizophrenia: a systematic review and meta-regression analysis.
    Psychiatry Res. 2026;367:117527.
    PubMed         Abstract available
    
    
13. AKKUS M, Karatas KS, Duman T, Kahya N, et al
    Changes in EASIX scores between acute psychotic episode and remission in patients with schizophrenia.
    Psychiatry Res. 2026;367:117544.
    PubMed         Abstract available
    
    

    
    Schizophr Res

14. BERNABEU T, Argote M, Citterio-Quentin A, Giloux N, et al
    Impact of cannabis use and cannabis composition on formal thought disorder and related brain networks: An fMRI study in 51 patients with schizophrenia.
    Schizophr Res. 2026;298:285-292.
    PubMed         Abstract available
    
    
15. JAKOB L, Mahayri TM, Koutrouli IRA, Kekrtova K, et al
    From gut to brain: A longitudinal assessment of intestinal permeability and immune activation markers in early-stage schizophrenia Spectrum disorders.
    Schizophr Res. 2026;298:275-284.
    PubMed         Abstract available
    
    
16. CAI C, Nyame MM, Alluri SCV, Chidrala C, et al
    Emergency department use disparities in schizophrenia: Mediating role of antipsychotic availability and administration.
    Schizophr Res. 2026;298:268-274.
    PubMed         Abstract available
    
    
17. SOSSOUMIHEN P, Dore J, Girard L, Thibaudeau E, et al
    Approach and avoidance in schizophrenia: The influence of comorbid social anxiety disorder and of social anxiety symptoms severity.
    Schizophr Res. 2026;298:261-267.
    PubMed         Abstract available
    
    
18. TRAN T, Woolridge SM, Bender K, Tang S, et al
    Differentiating predictors of physical and cognitive effort expenditure in early psychosis: A study of reinforcement environment, negative symptoms, and cognitive control.
    Schizophr Res. 2026;298:246-253.
    PubMed         Abstract available
    
    
19. BENO-RUIZ-DE-LA-SIERRA RM, Arjona-Valladares A, Osorio-Iriarte E, Sobrino-Conde L, et al
    Gamma-band network segregation links corollary discharge dysfunction and anomalous self-experiences in schizophrenia.
    Schizophr Res. 2026;298:237-245.
    PubMed         Abstract available
    
    
20. PARAS C, Nicolas CG, Lopez-Diaz A, Setien-Suero E, et al
    The exposome in schizophrenia: A systematic review of environmental risk indices.
    Schizophr Res. 2026;298:216-228.
    PubMed         Abstract available
    
    
21. COTRIK E, Da Silva AG
    Tolerability language and gastrointestinal risk in a meta-analysis of GLP-1 receptor agonists in antipsychotic-treated schizophrenia.
    Schizophr Res. 2026;298:214-215.
    PubMed        
    
    
22. LAVONIUS V, Lyytikainen LP, Sormunen E, Kahonen M, et al
    Polygenic risk for schizophrenia predicting age-specific fluctuations in depressive symptoms: Findings from the Young Finns Study.
    Schizophr Res. 2026;298:205-213.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Schizophrenia is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum